Optimer Pharmaceuticals Receives Milestone Licencing Payment

Optimer Pharmaceuticals

today announced it has received a $500,000 milestone payment from Cempra Pharmaceuticals pursuant to the terms of a licensing agreement between the companies. The milestone payment was made as a result of Cempra's continuing development of a next-generation macrolide (CEM-101) for the treatment of respiratory infections. Cempra licensed CEM-101 from Optimer and has successfully completed a Phase 1 study. "The successful completion of the CEM-101 Phase 1 study further validates our OPopS™ drug discovery platform. We are pleased to see this compound progress into the next phase of development by Cempra," said Pedro Lichtinger, Optimer's President and CEO. Learn how to find the best

for free.